Key facts
- This page summarizes Lorettta M. Itri's Form 4 filing for Aadi Bioscience, Inc. (WHWK).
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 04 Mar 2024, 19:18.
Lorettta M. Itri - 01 Mar 2024 Form 4 Insider Report for Aadi Bioscience, Inc. (WHWK)
- Reporting relationship
- CHIEF MEDICAL OFFICER
- Issuer ticker
- WHWK
- Reported as of
- 01 Mar 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2024, 19:18:03 UTC
- Prior SEC filing
- 02 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen Rodin, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Lorettta M. Itri filed Form 4 for Aadi Bioscience, Inc. (WHWK) on 04 Mar 2024.
Change
- Previous filing in this sequence was filed on 02 Mar 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AADI
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +76,813
- Change %
- Price
- $0.000000
- Shares after
- 76,813
- Date
- 01 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 76,813
- Exercise price
- $1.92
- Footnotes
- F1
AADI
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +60,000
- Change %
- Price
- $0.000000
- Shares after
- 60,000
- Date
- 01 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,000
- Exercise price
- $1.92
- Footnotes
- F2
AADI
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 01 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
One hundred percent (100%) of the shares subject to the option shall be fully vested on the Grant Date, subject to such Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the Grant Date. "Grant Date" shall mean March 1, 2024. This option comprises a portion of the Reporting Person's bonus for 2023 performance.
Footnote F2
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 1, 2024.
Footnote F3
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock.
Footnote F4
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024.